The Maris team evaluated the effect of dual CDK4/CDK6 inhibition on NB viability using the highly specific CDK4/6 inhibitor ribociclib (LEE011, Novartis Oncology, Basel, Switserland) showing the expected reduction in proliferation in 12 of 17 human NB-derived cell lines through cell-cycle arrest and cellular senescence [76]. The gene discussed is CDK6; the disease is neuroblastoma.